Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0107 • ACR Convergence 2025
Role of Achilles Elastography in Differentiating Patients with Early Psoriatic Arthritis
IRENE MARTIN MARTIN¹, CARMEN SAN JOSE MENDEZ², SONIA JIMENEZ BARRIOS³, ELENA MARTIN FERNANDEZ⁴, JULIA MIRANDA MANZANO⁵, DIEGO DIOS SANTOS⁶, JORGE GONZALEZ MARTIN⁷, PABLO ZURITA PRADA⁷, MONICA VAZQUEZ DIAZ⁸ and CARLOS GUILLEN-ASTETE⁹, ¹HOSPITAL VIRGEN DE LAS NIEVES, GRANADA, ²Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴HOSPITAL UNIVERSITARIO RAMON Y CAJAL, MADRID, ⁵FACULTAD BIOMEDICINA, MADRID, ⁶HOSPITAL DE VERÍN, OURENSE, ⁷HOSPITAL UNIVERSITARIO HM SANCHINARRO, MADRID, ⁸HOSPITAL UNIVERSITARIO HLA MONCLOA, MADRID, ⁹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: Elastography (EL) is an imaging technique that evaluates the biomechanical properties of tissues. Pathological tissues have different elastic properties compared to healthy tissues.In diseases…
Abstract Number: 0522 • ACR Convergence 2025
The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
Abdulrahman Y Almansouri¹, Jiayi Li², Ali Alhadri³, Keith Colaco⁴, Paula Harvey⁵, Shadi Ahktari⁶, Vinod Chandran⁷, Dafna D. Gladman⁸, Richard Cook² and Lihi Eder⁷, ¹King Faisal Specialist Hospital and Research Centre, University of Toronto and Women's College Hospital, Toronto, Canada, ²University of Waterloo, Waterloo, Canada, ³King Fahad Hospital, University of Toronto and Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada, ⁴University of Toronto, Toronto, Canada, ⁵University of Toronto Department of Medicine and Women's College Hospital, Toronto, ON, Canada, ⁶University of Toronto Department of Medicine and Women's College Hospital, Toronto, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk of developing cardiovascular diseases, including arrhythmias. Given that traditional cardiovascular disease risk factors are prevalent…
Abstract Number: 0877 • ACR Convergence 2025
Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
Rodrigo García Salinas¹, Gisel Reyes-Jara², Felicia Almada³, Juan Arguello² and Sebastian Magri⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano de La Plata, La Plara, Argentina, ⁴Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The transition from psoriasis (Pso) to psoriatic arthritis (PsA) presents an opportunity for early intervention and preventive strategies in high-risk patients with arthralgia. Objectives:…
Abstract Number: 0576 • ACR Convergence 2025
Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Laura Coates¹, Philip J. Mease², Joseph Merola³, Lourdes Perez Chada⁴, Dafna D. Gladman⁵, Alen Zabotti⁶, Ulrich Mrowietz⁷, mitsumasa kishimoto⁸, Cynthia Deignan⁹, Siddharth Chaudhari¹⁰, Lichen Teng¹¹ and Laure Gossec¹², ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Harvard Medical School, Wayland, MA, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ⁷Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Amgen, Inc., Agoura Hills, CA, ¹⁰Amgen Inc., Thousand Oaks, CA, ¹¹Amgen Inc., Thousand Oaks, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: FOREMOST (NCT03747939)1 offers novel insights on early oligoarticular (oligo, ≤4 active joints) PsA. Our aim was to analyse progression to polyarticular (poly; >4 active…
Abstract Number: 1098 • ACR Convergence 2025
Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Francisco Arias¹, Omar Hamdan², Asim Khanfar³, Kristel Barturen⁴ and Roa’a Alshajrawi⁵, ¹University of Texas Rio Grande Valley, McAllen, TX, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Rochester, NY, ⁴Universidad San Martin de Porres, McAllen, TX, ⁵University of Jordan, Amman, 'Amman, Jordan
Background/Purpose: Apremilast, a PDE-4 inhibitor, is commonly indicated for patients with psoriasis as well as Behçet’s disease. Although this medication is generally well tolerated, numerous…
Abstract Number: 1427 • ACR Convergence 2025
Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Ricardo I. De la Rosa-Vazquez⁵, Victoria P. Limas-Martínez⁵, Annette Dominguez-Guerra⁵, Jesus Alberto Cardenas-de la Garza⁶, Iris J. Colunga-Pedraza³, Dionicio A. Galarza-Delgado³, Jose R Azpiri-Lopez⁷, Victor M Fraga-Enriquez⁸ and Diego Azamat Salcedo Almanza⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁸Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁹Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased cardiovascular (CV) risk due to a higher prevalence of comorbidities and chronic systemic inflammation. In those…
Abstract Number: 1460 • ACR Convergence 2025
Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Stefan Siebert¹, Mohamed Sharaf², Frank Behrens³, Proton Rahman⁴, mitsumasa kishimoto⁵, Enrique R. Soriano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Ruben Queiro¹⁰, Ennio Lubrano¹¹ and Laure Gossec¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁴Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ¹¹Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Work impairment is a key issue in PsA. Biologic treatments can improve work status in patients (pts) with PsA; however, there is lack of…
Abstract Number: 1945 • ACR Convergence 2025
Significance of Finger Joint Tenderness With or Without Swelling in Relation to MRI, Ultrasound, and X-Ray Findings in Psoriatic Arthritis_Final results
Victoria Furer¹, iris Eshed², Moshe Iluz¹, Ori Elkayam³ and Ari Polachek⁴, ¹Tel-Aviv Medical Center, Tel-Aviv, Israel, ²Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer affiliated with School of Medicine, Tel Aviv University, Tel Aviv, Israel, ³Tel Aviv medical center, Tel Aviv, Israel, ⁴Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel
Background/Purpose: Musculoskeletal involvement in psoriatic arthritis (PsA) affects both articular and extra-articular structures, presenting as inflammatory and structural lesions. The relationship between tender and/or swollen…
Abstract Number: 2323 • ACR Convergence 2025
Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
Mitndbaim Parra¹, Marta Flores², María Ángeles Puche-Larrubia³, Alejandro Escudero Contreras⁴, María Dolores López-Montilla⁵ and Clementina López Medina⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Spain, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic rheumatic disease that develops in up to one-third of patients with psoriasis. Identifying predictive factors for PsA in…
Abstract Number: 2363 • ACR Convergence 2025
Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Milad Heydari-Kamjani¹, Jennifer Murphy² and Marina Magrey³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland Medical Center, cleveland, OH, ³Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE), yet the comparative safety of…
Abstract Number: 2686 • ACR Convergence 2025
Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Koray Tascilar¹, Alp Temiz¹, Filippo Fagni², Arnd Kleyer³, Louis Schuster¹, Stephan Kemenes¹, Sara Bayat¹, David Simon⁴ and Georg Schett⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ³Charite Universitätsmedizin Berlin, Erlangen, Bayern, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁵Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: RA and PsA follow different pathomechanisms and incur disease-specific erosive and osteoproliferative bone changes. We used data from a large cohort of RA and…
Abstract Number: 0108 • ACR Convergence 2025
In Vivo and In Vitro Analysis of IL-23 Modulation Following Anti-TNF Therapy in Psoriatic Arthritis
Jesús Eduardo Martín Salazar¹, Clementina López Medina², Carlos Pérez Sánchez³, María Ángeles Puche-Larrubia⁴, Pedro Ortiz Buitrago⁵, María Dolores López-Montilla⁶, Iván Arias de la Rosa⁷, Laura Cuesta López⁸, Miriam Ruiz Ponce⁸, Antonio Barranco⁸, Laura Romero Zurita⁸, Elena Moreno-Caño⁹, Rafaela Ortega-Castro¹⁰, Jerusalén Calvo¹¹, M Carmen Abalos-Aguilera¹², Desiree Ruiz-Vilchez¹³, Chary López pedrera¹⁴, Alejandro Escudero Contreras¹¹, Eduardo Collantes estévez¹⁵ and Nuria Barbarroja¹⁶, ¹Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, ²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁴Reina Sofia University Hospital, Granada, Spain, ⁵Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁶Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁷IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, ⁸Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Córdoba, Spain, ⁹IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹¹IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹³Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹⁵Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease for which TNFα inhibitors are the standard first-line biologic therapy. Nonetheless, a significant proportion of patients…
Abstract Number: 0523 • ACR Convergence 2025
SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
Jennifer Soung¹, Virginie Kelly², Marni Wiseman³, Adrian Rodriguez⁴, Theodore Alkousakis⁵, Olivia Choi⁵, Daphne Chan⁵, Katelyn Rowland⁵, Linda Hou⁶, Jenny Jeyarajah⁷, Nastaran Abbarin⁸, Elizabeth Skobelev⁵, Sancharitha Ramji⁵, James Krell⁹, Max Sauder¹⁰ and David Adam¹¹, ¹Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ²Saint-Louis Medical Clinic, Quebec, Canada, Quebec, Canada, ³SkinWise Dermatology, Manitoba, Canada, Manitoba, Canada, ⁴Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA, Nashville, TN, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, ⁷Johnson & Johnson, Horsham, PA, USA, Horsham, ⁸Janssen Inc, Toronto, ON, Canada, Toronto, Canada, ⁹Total Skin & Beauty Dermatology Center, Birmingham, AL, USA, Birmingham, ¹⁰Probity Medical Research, ON, Canada; University of Toronto, ON, Canada, Toronto, Canada, ¹¹CCA Medical Research, ON, Canada, Toronto, Canada
Background/Purpose: Even low body surface area (BSA) psoriasis can be extremely bothersome to patients and can have a significant impact on their lives just as…
Abstract Number: 0878 • ACR Convergence 2025
Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study
Maria Gabriella Raimondo¹, Hashem Mohammadian², Simon Rauber³, Stefano Alivernini⁴, Filippo Fagni⁵, Giulia Corte⁶, Koray Tascilar⁷, Alina Mihaela Ramming⁸, Juergen Rech², Maria Antonietta D´Agostino⁹, Georg Schett², Milena Pachowsky⁸, Arnd Kleyer¹⁰ and Andreas Ramming¹¹, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, ⁴Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁶- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Internal Medicine ³ – Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹⁴Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, ¹⁰Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹¹Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Enthesitis is an early event in the course of psoriatic arthritis (PsA) and a hallmark feature of the disease. Currently, much of the understanding…
Abstract Number: 0577 • ACR Convergence 2025
Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
Laure Gossec¹, Mohamed Sharaf², Xenofon Baraliakos³, mitsumasa kishimoto⁴, Ruben Queiro⁵, Ennio Lubrano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Enrique R. Soriano¹⁰, Proton Rahman¹¹, Frank Behrens¹² and Stefan Siebert¹³, ¹Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Kyorin University School of Medicine, Tokyo, Japan, ⁵Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ⁶Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹¹Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ¹²Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ¹³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Randomized controlled trials have demonstrated the efficacy of IL-23 inhibitors (i) and IL-17i in PsA; however, real-world data on their effectiveness in heterogeneous patient…

« Previous Page
1
…
4
5
6
7
8
…
93
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].